<div class="container">

<table style="width: 100%;"><tr>
<td>SimPhase123</td>
<td style="text-align: right;">R Documentation</td>
</tr></table>
<h2>Simulates replications of the phase123 and phase 12-3 trials.</h2>

<h3>Description</h3>

<p>This function simulates replications of the phase123 and phase 12-3 trials and returns a list containing the doses chosen, decisions made (1=A(x) better, 0= futility, -1=C better)
</p>


<h3>Usage</h3>

<pre><code class="language-R">SimPhase123(DoseStart, Dose, PE, PT, Hypermeans, Hypervars, Contour, PiLim,
  ProbLim, NET, NF, Accrue12, Time12, cohort, betaA, ProbC, betaC, Family,
  alpha, Nmax, Accrue, Twait, NLookSwitch, NLook, Sup, Fut, nSims)
</code></pre>


<h3>Arguments</h3>

<table>
<tr style="vertical-align: top;">
<td><code>DoseStart</code></td>
<td>
<p>Starting dose of the phase 12 trial.</p>
</td>
</tr>
<tr style="vertical-align: top;">
<td><code>Dose</code></td>
<td>
<p>Vector of standardized doses considered in the trial.</p>
</td>
</tr>
<tr style="vertical-align: top;">
<td><code>PE</code></td>
<td>
<p>True efficacy dose-toxicity vector.</p>
</td>
</tr>
<tr style="vertical-align: top;">
<td><code>PT</code></td>
<td>
<p>True toxicity dose-toxicity vector.</p>
</td>
</tr>
<tr style="vertical-align: top;">
<td><code>Hypermeans</code></td>
<td>
<p>Prior Means for the Eff-Tox design of length 6.</p>
</td>
</tr>
<tr style="vertical-align: top;">
<td><code>Hypervars</code></td>
<td>
<p>Prior Variances for the Eff-Tox design of length 6.</p>
</td>
</tr>
<tr style="vertical-align: top;">
<td><code>Contour</code></td>
<td>
<p>Vector containing 4 entries used to make the desireability function. Contour[1] contains a desired toxicity probability given efficacy, Countour[2] contains a desired efficacy probability given toxicity, and (Contour[3],Contour[4]) is an equally desireable pair of efficacy and toxicity probabilities that are non-zero or one.</p>
</td>
</tr>
<tr style="vertical-align: top;">
<td><code>PiLim</code></td>
<td>
<p>Vector of length two with PiLim[1] containing the acceptable lower limit on efficacy probability and PiLim[2] containing the acceptable upper limit on toxicity probability.</p>
</td>
</tr>
<tr style="vertical-align: top;">
<td><code>ProbLim</code></td>
<td>
<p>Vector of length two with ProbLim[1] containing the probability cutoff for acceptable efficacy probability and ProbLim[2] containing the probability cutoff for acceptable toxicity probability.</p>
</td>
</tr>
<tr style="vertical-align: top;">
<td><code>NET</code></td>
<td>
<p>Maximum sample size of the phase 12 trial.</p>
</td>
</tr>
<tr style="vertical-align: top;">
<td><code>NF</code></td>
<td>
<p>Number of patients to assign deterministic doses prior to adaptive randomization.</p>
</td>
</tr>
<tr style="vertical-align: top;">
<td><code>Accrue12</code></td>
<td>
<p>Accrual rate for patients in the phase 12 portion of the trial.</p>
</td>
</tr>
<tr style="vertical-align: top;">
<td><code>Time12</code></td>
<td>
<p>Time window for phase 12.</p>
</td>
</tr>
<tr style="vertical-align: top;">
<td><code>cohort</code></td>
<td>
<p>Size of each patient cohort.</p>
</td>
</tr>
<tr style="vertical-align: top;">
<td><code>betaA</code></td>
<td>
<p>True linear term for the rate or mean parameter (beta_1,exp(beta_E),-exp(beta_T),beta_2,beta_0) for agent A.</p>
</td>
</tr>
<tr style="vertical-align: top;">
<td><code>ProbC</code></td>
<td>
<p>Probability of efficacy and toxicity for the control therapy.</p>
</td>
</tr>
<tr style="vertical-align: top;">
<td><code>betaC</code></td>
<td>
<p>Linear term for efficacy, toxicity and beta_0 for the control groupar term for efficacy, toxicity and beta_0 for the control group.</p>
</td>
</tr>
<tr style="vertical-align: top;">
<td><code>Family</code></td>
<td>
<p>Time to event distribution. Options include: Exponential, Gamma, Weibull, Lognormal.</p>
</td>
</tr>
<tr style="vertical-align: top;">
<td><code>alpha</code></td>
<td>
<p>Shape parameter or standard deviation of a lognormal distribution.</p>
</td>
</tr>
<tr style="vertical-align: top;">
<td><code>Nmax</code></td>
<td>
<p>Maximum number of patients to enroll in phase 3.</p>
</td>
</tr>
<tr style="vertical-align: top;">
<td><code>Accrue</code></td>
<td>
<p>Accrual rate for patients in the phase 3 portion of the trial.</p>
</td>
</tr>
<tr style="vertical-align: top;">
<td><code>Twait</code></td>
<td>
<p>Waiting time in between phase 12 and phase 3.</p>
</td>
</tr>
<tr style="vertical-align: top;">
<td><code>NLookSwitch</code></td>
<td>
<p>Number of patient events to determine if we re-optimize doses for A.</p>
</td>
</tr>
<tr style="vertical-align: top;">
<td><code>NLook</code></td>
<td>
<p>Vector of information criteria for making interim looks.</p>
</td>
</tr>
<tr style="vertical-align: top;">
<td><code>Sup</code></td>
<td>
<p>Vector of superiority boundaries.</p>
</td>
</tr>
<tr style="vertical-align: top;">
<td><code>Fut</code></td>
<td>
<p>Vector of futility boundaries.</p>
</td>
</tr>
<tr style="vertical-align: top;">
<td><code>nSims</code></td>
<td>
<p>Number of simulations to run for the phase 123 and conventional design.</p>
</td>
</tr>
</table>
<h3>References</h3>

<p>[1] Chapple and Thall (2018).A Hybrid Phase I-II/III Clinical Trial Design Allowing Dose Re-Optimization in Phase III. Biometrics. In Press,
</p>


<h3>Examples</h3>

<pre><code class="language-R"> ##We need to specify Phase 12,
###Phase 3 trial paramters,
##the additional phase 123 parameters and simulation parameters
#This is scenario 3 for the exponetial case
##the additional phase 123 parameters and simulation parameters
###########PHASE12 Parameters ##################
DoseStart=1
##True Efficacy and Toxicity Probabilities
PT = c(.05,.08,.1,.15,.2)
PE=c(.2,.25,.35,.4,.55)
##Raw Dose Levels considered
Dose = c(1,2,3,3.5,5)
#Max Sample Size
NET=30
##Number of patients before randomization
NF=15
##Cohort size
cohort=3
##Hypermeans for Eff-Tox
Hypermeans = c(.022,3.45,0,-4.23,3.1,0)
Hypervars = c(2.6761, 2.6852, .2, 3.1304, 3.1165, 1)
Hypervars=Hypervars^2
##Contour Vector
Contour = c(.35, .75,.7,.4)
##Acceptability Criteria
PiLim = c(.3,.4)
ProbLim=c(.1,.1)
##Phase 12 accrual rate
Accrue12=5
###How long is the time window in phase 12?
Time12=1
##########PHASE3 Parameters####################
Nmax=500
##Number of patient events for interim looks
NLook = c(200,300,400)
##Superiority Boundaries
Sup = c(2.96, 2.53,1.99)
##Futility Boundaries (0 means no futility decision)
Fut = c(0,1.001,0)
##Average accrual rate for phase III
Accrue = 10
###########Phase123 Parameters###########
###Number of patient events to re-optimize doses
NLookSwitch=50
##Time in between phase 12 and phase 3
Twait=1
#########Simulation Parameters######
###Family of Distributions
Family="Gamma"
###Shape parameter, Not needed for Exponential
alpha=1
###True Beta vector (beta_1,exp(beta_E),-exp(beta_T),beta_2,beta_0)
betaA = c(.1, .3, -1,-1,3.6)
##True beta vector for (exp(beta_E),-exp(beta_T),beta_C)  of the control treatment
betaC=c(.3,-1,log(24/1.035111))
##True efficacy and toxicity probability for control group
ProbC = c(.3,.1)
##Number of simulations to run
nSims=1
##Run Simulations
Results=SimPhase123(DoseStart,Dose,PE,PT,Hypermeans,Hypervars,Contour,
                 PiLim,ProbLim,NET,NF,Accrue12,Time12,cohort,betaA,ProbC,betaC,
                Family,alpha,Nmax,Accrue,Twait,NLookSwitch,NLook,Sup,Fut,nSims)
</code></pre>


</div>